The Children’s Oncology Group anticoagulant prophylaxis phase 3 study (ACCL 1333) is currently testing the efficacy of Apixaban for primary VTE prevention versus no anticoagulation during induction chemotherapy in children with newly diagnosed ALL treated with asparaginase [25]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.